Breaking News

Almac Launches Second Line for High Throughput GMP Peptide

New facility will be based in Edinburgh

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Almac Group has brought online a second stream for high throughput GMP peptide manufacturing. The new facility, based in Edinburgh, Scotland, manufactures neoantigen derived peptides for use in the production of patient specific, individualized cancer vaccines.   Almac has been active in high throughput manufacturing of neoantigen derived peptides—branded by Almac as NeoPeptides—for several years. The NeoPeptides facility underwent a conversion from non GMP to GMP through 2018 and has been ope...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters